Design and stability of pediatric oral formulation of imatinib.

Mélanie HinterlangAmandine GendronThomas FleuryAndré RieutordAnastasia VranaJoel SchlatterMaxime Annereau

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2021)

The stability study showed that the imatinib oral solution at a concentration of 30 mg/mL provides an alternative option at the commercial tablet dosage forms for pediatric patients and patients who have difficulties to swallow.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
drug delivery
peritoneal dialysis
patient reported outcomes
young adults